Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model

Bressand, Diane; Novell, Anthony; Girault, Alban; Raoul, William; Fromont-Hankard, G.; Escoffre, Jean‐Michel; Lecomte, Thierry; Bouakaz, Ayache

doi:10.1021/acs.molpharmaceut.9b00416

Cited by 29 publications

(26 citation statements)

References 58 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study showed that the ultrasound microbubbles treatment group presented significant tumor growth inhibition (67). In addition, the use of nab-paclitaxel combined with ultrasound microbubbles significantly inhibited the activity of PDAC tumor cells in vitro and reduced the tumor volume in a subcutaneous PDAC mouse model (68). Furthermore, a clinical trial evaluated the efficacy of focused ultrasound combined with microbubble delivery of gemcitabine in PDAC patients.…”

Section: Remodeling Tumor Vasculaturementioning

confidence: 99%

Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?

et al. 2020

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with one of the worst prognoses worldwide and has an overall 5-year survival rate of only 9%. Although chemotherapy is the recommended treatment for patients with advanced PDAC, its efficacy is not satisfactory. The dense dysplastic stroma of PDAC is a major obstacle to the delivery of chemotherapy drugs and plays an important role in the progression of PDAC. Therefore, stroma-targeting therapy is considered a potential treatment strategy to improve the efficacy of chemotherapy and patient survival. While several preclinical studies have shown encouraging results, the anti-tumor potential of the PDAC stroma has also been revealed, and the extreme depletion might promote tumor progression and undermine patient survival. Therefore, achieving a balance between stromal abundance and depletion might be the further of stroma-targeting therapy. This review summarized the current progress of stroma-targeting therapy in PDAC and discussed the doubleedged sword of its therapeutic effects.

show abstract

Section: Remodeling Tumor Vasculaturementioning

confidence: 99%

Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…PTX toxicity arises not only from the drug itself but also from the high concentration of the Cremophor EL vehicle, which is required to solubilize the poorly aqueous PTX into an injectable solution. The most common toxicities associated with Cremophor EL include acute hypersensitivity reactions, which are recognizable as flushing, rash, dyspnea and tachycardia (Bhatt et al, 2019; Bressand et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Characterization of an Amphiphilic Phosphonated Calixarene Carrier Loaded With Carboplatin and Paclitaxel: A Preliminary Study to Treat Colon Cancer in vitro and in vivo

Mao

Chen

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The inadequacy of available detection methods and a naturally aggressive progression have made colon cancer the third most common type of cancer, accounting for ~10% of all cancer cases. The heterogeneity and genomic instability of colon cancer tumors make current treatments unsatisfactory. This study evaluated a novel nanoscale delivery platform comprising phosphonated calixarenes (P4C6) co-loaded with paclitaxel (PTX) and carboplatin (CPT). The nanoparticles showed average hydrodynamic sizes of 84 ± 8 nm for empty P4C6 nanoparticle and 119 ± 13 nm for PTX-CPT-P4C6. The corresponding zeta potentials were −40.8 ± 8.8 and −35.4 ± 4.2 mV. The optimal CPT:PTX ratio was 5.22:1, and PTX-CPT-P4C6 with this ratio was more cytotoxic against HT-29 cells than against Caco-2 cells (IC50, 0.4 ± 0.02 vs. 2.1 ± 0.3 μM), and it induced higher apoptosis in HT-29 cells (56.6 ± 4.5 vs. 44.9 ± 3.44%). PTX-CPT-P4C6 inhibited the invasion and migration of HT-29 cells more strongly than the free drugs. It also inhibited the growth of HT-29 tumors in mice to the greatest extent of all formulations, with negligible side effects. This research demonstrates the potential of P4C6 to deliver two chemotherapeutic agents to colon cancer tumors to provide synergistic efficacy than single drug administration.

show abstract

“…combined MBs‐assisted US with Nab‐paclitaxel to enhance intracellular uptake and significantly improve the therapeutic effectiveness of Nab‐paclitaxel in PDAC models. [ 259 ]…”

Section: Pdac‐tailored Nanomaterials For Therapeutic Strategiesmentioning

confidence: 99%

Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma

Xia

Lee

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis and treatment. In recent decades, nanomaterials have received increasing attention for diagnosis and therapy of PDAC. However, these designs are mainly focused on the macroscopic tumor therapeutic effect, while the crucial nano–bio interactions in the heterogeneous microenvironment of PDAC remain poorly understood. As a result, the majority of potent nanomedicines show limited performance in ameliorating PDAC in clinical translation. Therefore, exploiting the unique nature of the PDAC by detecting potential biomarkers together with a deep understanding of nano–bio interactions that occur in the tumor microenvironment is pivotal to the design of PDAC‐tailored effective nanomedicine. This review will introduce tailor‐made nanomaterials‐enabled laboratory tests and advanced noninvasive imaging technologies for early and accurate diagnosis of PDAC. Moreover, the fabrication of a myriad of tailor‐made nanomaterials for various PDAC therapeutic modalities will be reviewed. Furthermore, much preferred theranostic multifunctional nanomaterials for imaging‐guided therapies of PDAC will be elaborated. Lastly, the prospects of these nanomaterials in terms of clinical translation and potential breakthroughs will be briefly discussed.

show abstract

Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model

Cited by 29 publications

References 58 publications

Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?

Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?

Characterization of an Amphiphilic Phosphonated Calixarene Carrier Loaded With Carboplatin and Paclitaxel: A Preliminary Study to Treat Colon Cancer in vitro and in vivo

Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About